KDR and renal cell carcinoma: These results indicate that ART exerts its anti-angiogenic effects by directly targeting VEGFR2 on the surface of endothelial cells and further antagonizing the VEGFR2-mediated downstream signaling cascade, indicating that ART may be well-tolerated and could potentially be used as an anti-angiogenic agent in RCC.